Alterations of the retinoblastoma gene in metastatic breast cancer.
Germline mutations affecting the retinoblastoma gene (RB1) predispose to inherited retinoblastomas but also other malignancies, including breast cancer. While somatic RB1 mutations have been detected in different malignancies, information about the potential role of RB1 mutations in breast cancer is limited. Recently, we discovered RB1 mutations to be associated with resistance to anthracyclines/mitomycin in primary breast cancer. The present work is the first report evaluating RB1 mutation and epigenetic status in metastatic breast cancer. Among 148 breast cancer samples analyzed by MLPA, four samples harbored intragenic deletions/duplications: Thus, exons 1-2 were deleted in two tumors and exons 21-23 in one tumor, while one sample harbored duplication of exons 18-23. The entire RB1 gene was duplicated in two tumors and multiple amplifications were revealed in one sample. Reduced copy number was observed in 17 samples (11.5%). No point mutation or promoter hypermethylation was discovered (n = 38 and 114 tumors analyzed, respectively). Interestingly, among seven tumors expressing lack of response to epirubicin, two samples harbored alterations in RB1, contrasting none out of 16 tumors with stable disease or an objective response (P = 0.08). In summary, the frequency of RB1 alterations in metastatic lesions was not increased when compared to primary breast cancer, indicating that RB1 alterations do not play a major role in metastatic development. While a non-significant association suggesting RB1 alterations to be linked to therapy resistance was observed, our data do not suggest a major role for RB1 alterations explaining acquired drug resistance.
Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway.
Elisabet Ognedal
EO
Berge
Stian
S
Knappskog
Johan Richard
JR
Lillehaug
Per Eystein
PE
Lønning
D000328:Adult; D018943:Anthracyclines / Q000494:pharmacology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D019008:Drug Resistance, Neoplasm; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D016161:Genes, Retinoblastoma; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin / Q000494:pharmacology; D009154:Mutation; D009362:Neoplasm Metastasis / Q000473:pathology*; D016160:Retinoblastoma Protein / Q000235:genetics* / Q000627:therapeutic use*
D018943:Anthracyclines; D016160:Retinoblastoma Protein; D016685:Mitomycin
Prostate. 1995 Dec;27(6):314-20
7501543
Pathol Int. 1994 Jan;44(1):34-8
8025647
Science. 2006 Oct 13;314(5797):268-74
16959974
Cancer Res. 2000 Mar 1;60(5):1211-6
10728677
Am J Pathol. 1999 Jul;155(1):267-74
10393858
Mol Carcinog. 2000 Nov;29(3):151-8
11108660
BMC Genet. 2005 Nov 04;6:53
16269091
Cancer Res. 2003 Aug 1;63(15):4588-93
12907636
Cancer Res. 1992 May 15;52(10):2991-4
1581913
Hum Pathol. 1999 Dec;30(12):1435-40
10667421
Cancer Res. 1997 Jun 1;57(11):2229-37
9187126
Science. 2007 Nov 16;318(5853):1108-13
17932254
Nature. 2007 Mar 8;446(7132):153-8
17344846
Genes Chromosomes Cancer. 1999 Mar;24(3):183-90
10451697
Mol Cancer Res. 2005 Feb;3(2):71-7
15755873
Nature. 2000 Aug 17;406(6797):747-52
10963602
Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3
5279523
Cell. 1995 May 5;81(3):323-30
7736585
Blood. 2007 Jun 15;109(12):5422-9
17332242
J Natl Cancer Inst. 2008 Dec 17;100(24):1771-9
19066271
Nature. 2009 Apr 9;458(7239):719-24
19360079
Mol Biol (Mosk). 2003 Jul-Aug;37(4):696-703
12942643
Mol Cancer. 2010 Jul 01;9:173
20594292
J Clin Oncol. 1996 Aug;14(8):2197-205
8708708
Trends Mol Med. 2004 Mar;10(3):113-8
15102353
Am J Respir Cell Mol Biol. 1998 Feb;18(2):188-96
9476905